Gilead Sciences or Regeneron Pharmaceuticals: Which Stock Has More Upside?
Even as Regeneron Pharmaceuticals surged 12% during the past Day, its peer Gilead Sciences may be a better choice. Consistently evaluating alternatives is core to sound investment approach. Gilead Sciences (GILD) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Regeneron Pharmaceuticals (REGN) stock, suggesting you may be better off investing in GILD
- GILD’s quarterly revenue growth was 1.8%, vs. REGN’s 0.9%.
- In addition, its Last 12 Months revenue growth came in at 3.8%, ahead of REGN’s 2.9%.
- GILD leads on profitability over both periods – LTM margin of 37.4% and 3-year average of 39.2%.
You can’t predict the next crash, but you can prepare. See how High Quality Portfolio helps you.
REGN develops and markets medicines for diseases including wet macular degeneration, diabetic edema, atopic dermatitis, asthma, and rheumatoid arthritis worldwide. GILD develops and commercializes medicines addressing unmet medical needs worldwide, specializing in HIV/AIDS treatments including Biktarvy, Genvoya, Descovy, and others.
Valuation & Performance Overview
| REGN | GILD | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 17.8 | 13.6 | GILD |
| Revenue Growth | |||
| Last Quarter | 0.9% | 1.8% | GILD |
| Last 12 Months | 2.9% | 3.8% | GILD |
| Last 3 Year Average | 1.4% | 1.6% | GILD |
| Operating Margins | |||
| Last 12 Months | 26.7% | 37.4% | GILD |
| Last 3 Year Average | 30.0% | 39.2% | GILD |
| Momentum | |||
| Last 3 Year Return | -12.5% | 65.5% | GILD |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: REGN Revenue Comparison | GILD Revenue Comparison
See more margin details: REGN Operating Income Comparison | GILD Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell GILD Stock to see if Gilead Sciences’s edge holds up under the hood or if Regeneron Pharmaceuticals still has cards to play (see Buy or Sell REGN Stock).
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| REGN Return | 29% | 31% | 14% | 22% | -19% | -17% | 55% | ||
| GILD Return | -7% | 30% | 24% | -2% | 19% | 30% | 133% | <=== | |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 110% | ||
| Monthly Win Rates [3] | |||||||||
| REGN Win Rate | 50% | 67% | 50% | 58% | 50% | 44% | 53% | ||
| GILD Win Rate | 33% | 58% | 33% | 42% | 67% | 67% | 50% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 67% | 64% | <=== | |
| Max Drawdowns [4] | |||||||||
| REGN Max Drawdown | -10% | -8% | -13% | -6% | -20% | -32% | -15% | ||
| GILD Max Drawdown | -9% | 0% | -20% | -12% | -21% | -3% | -11% | <=== | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | ||
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 10/28/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read REGN Dip Buyer Analyses to see how the stock has fallen and recovered in the past.